FGFR2 and urothelial carcinoma: However, dovitinib did not show clinical benefit in endometrial cancer with FGFR2 mutations, glioblastoma with FGFR3‐TACC3 gene fusion and urothelial carcinoma with FGFR3 mutations or overexpression.63, 152